Clinical Trials
50 trialsTherapy for Advanced NSCLC With EGFR 19delins Mutation
Fuzhou General Hospital
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
Massachusetts General Hospital
NEGOTIATE
Sun Yat-sen University
A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Novartis
IRENE
Amsterdam UMC, location VUmc
LADIE
Intergroupe Francophone de Cancerologie Thoracique
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Boehringer Ingelheim
ADJUVANT
Guangdong Association of Clinical Trials
Psychometric Properties of the EORTC QLQ-LC29
University Hospital Regensburg
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
AstraZeneca
Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma
Shanghai University of Traditional Chinese Medicine
High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Dana-Farber Cancer Institute
Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR
Qilu Pharmaceutical Co., Ltd.
Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)
National Cancer Center, Korea
Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
Wake Forest University Health Sciences
Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC
University Health Network, Toronto
Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations
Chinese Society of Lung Cancer
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Iressa Follow-up Trial
AstraZeneca
TIDAL1
Papworth Hospital NHS Foundation Trust
ICARUS
AstraZeneca
Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene
Memorial Sloan Kettering Cancer Center
Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
University of Alabama at Birmingham
CURCUMIN
Lady Davis Institute
Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma
Tang-Du Hospital
A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
AVEO Pharmaceuticals, Inc.
ARPEGE
Assistance Publique - Hôpitaux de Paris
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Massachusetts General Hospital
Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
H. Lee Moffitt Cancer Center and Research Institute
Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Swiss Cancer Institute
Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases
Swiss Cancer Institute
Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer
SCRI Development Innovations, LLC
First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker
National Cancer Center, Korea
A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer
Stanford University
First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
AstraZeneca
Phase II Iressa & Carbo/Gem in NSCLC
AstraZeneca
Phase II Iressa Versus Vinorelbine (INVITE)
AstraZeneca
Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer
West Japan Thoracic Oncology Group